SecBot SecBot
PRESS-RELEASE ·Filed Mar 3, 2026

ESPR

Esperion Therapeutics, Inc.
BULLISH
Impact 8/10
Horizonmonths Processed8mo ago WireGlobeNewswire
Press release · M&A
Actionable Insight ▲ Bullish

Traders should monitor Enbumyst's commercial ramp-up, future milestone achievements, and integration into Esperion’s sales infrastructure. The acquisition significantly expands Esperion’s addressable market and could drive re-rating if sales meet expectations. Watch for commentary on profitability and cash runway during the March 3 conference call.

DirectionBullish
Confidencehigh
Horizonmonths

How the stock moved after the report

BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$2.91
T+0 close · Mar 3, 2026 · via day close
Latest settled
+7.56%
T+60 · $3.13
Vs SPY
−2.76%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Mar 3 $2.91entry
  2. T+1 · 9mo ago 0.00%α −0.76% · $2.91
  3. T+5 · 8mo ago −7.22%α −6.74% · $2.70
  4. T+20 · 8mo ago −5.84%α −1.44% · $2.74
  5. T+60 · 6mo ago +7.56%α −2.76% · $3.13
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Esperion Therapeutics is acquiring Corstatis Therapeutics to gain full rights to Enbumyst™, the first FDA-approved nasal spray diuretic for edema associated with congestive heart failure, liver, and kidney disease. The deal includes a $75 million upfront cash payment, up to $180 million in potential milestone payments, and low double-digit royalties on future sales, with financing from existing credit facilities and royalty monetization. The acquisition expands Esperion’s cardiovascular portfolio and leverages its commercial infrastructure to target a U.S. market opportunity exceeding $4 billion.

Key Financial Metrics

Deal Value
$255.0M

Key Facts

  • Esperion is acquiring Corstasis Therapeutics to add Enbumyst™ (bumetanide nasal spray) to its portfolio.
  • Enbumyst is the first and only FDA-approved nasal spray loop diuretic, approved in September 2025 for edema in CHF, hepatic, and renal disease.
  • Deal includes $75 million upfront cash payment, up to $180 million in milestone payments, and low double-digit royalties on global sales.
  • Transaction expected to close in Q2 2026, financed through existing credit facilities and royalty monetization with Athyrium and HealthCare Royalty.
  • Enbumyst targets a U.S. market opportunity exceeding $4 billion, with potential expansion into nephrotic syndrome and other indications.
  • Acquisition aligns with Esperion’s Vision 2040 and complements its established cardiovascular commercial platform.

Financial Impact

$75 million upfront cash outlay, $180 million in potential milestone payments, and royalty obligations; expected to accelerate double-digit revenue growth

revenuecash_flowdilutiondebt

Risk Factors

  • Failure to achieve anticipated commercial uptake of Enbumyst
  • Integration risks and execution challenges in scaling a new product
  • Potential dilution or increased leverage from financing structure
  • Forward-looking statements may not materialize as expected

Market Snapshot

Exchange
Nasdaq

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3248116

Track record

21 reports on ESPR

Performance horizon

4 of 6 bullish or bearish reports moved the stock their way by T+20. Best: +16.30% at T+60 after the Mar 10, 2026 report. 5 of 7 went positive at some point.

Filters
  1. Nov 10, 20266d ago SC 13G/A Bearish 4/10 No price data
  2. Sep 3, 202610w ago Court Ruling Bullish 5/10 No price data
  3. Aug 13, 202613w ago Institutional Cluster Bearish 5/10 No price data
  4. Jul 23, 202616w ago 15-12G Neutral 5/10 No price data
  5. Jul 16, 202617w ago EFFECT Bearish 5/10 Entry $3.18 No price data
  6. Jul 16, 202617w ago EFFECT Bearish 5/10 Entry $3.18 No price data
  7. Jul 13, 202618w ago 25-NSE Bullish 7/10 Entry $3.19 No price data
  8. Jul 13, 202618w ago 8-K Bullish 7/10 Entry $3.19 No price data
  9. Jun 16, 202621w ago DEFA14A Bullish 6/10 Entry $3.17 No price data
  10. Jun 11, 202622w ago Institutional Cluster Mixed 4/10 Entry $3.15 to $3.19 ▲ +1.27% −0.62% vs SPY
Showing 10 of 21

US Market Status

Market Closed · Opens in 6h 42m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Mar 3, 2026